ArticlePediatric nephrology (Berlin, Germany)2026
Relationships between galectin-3, sclerostin and arterial stiffness in children with renal scar.
Article in Pediatric nephrology (Berlin, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundRenal scar can lead to hypertension and cardiovascular disease in children. Arterial stiffness is an important endpoint in the development of cardiovascular diseases and is a guide in the recognition of subclinical cardiovascular events. This study aimed to investigate oscillometric arterial stiffness data and sclerostin and galectin-3 levels in children with renal scar.
methodsPatients aged 5-18 years with renal scar and controls were included. Arterial stiffness parameters were measured by oscillometric method. Sclerostin, galectin-3 and NGAL levels were determined by ELISA method.
results108 patients and 66 controls were included. The patients had higher C-reactive protein (CRP) values and lower glomerular filtration rate (GFR) (p = 0.013, p = 0.005, respectively). Serum sclerostin levels, urine NGAL/creatinine (cr) and sclerostin/cr, galectin-3/cr, augmentation index, reflection magnitude and augmentation pressure were higher in patients (p = 0.026, p = 0.047, p = 0.000, p = 0.000, p = 0.013, p = 0.03, p = 0.02, respectively). Serum sclerostin was positively correlated with CRP and augmentation index (r = 0.22, p = 0.044; r = 0.355, p = 0.003, respectively). Urinary galectin-3/cr and NGAL/cr values were positively correlated with each other (r = 0.544, p = 0.000). Urinary galectin-3/cr was higher in patients with proteinuria than in those without proteinuria (p = 0.000). A ROC analysis showed that galectin-3/cr was predictive of proteinuria (area under the curve:0.726 ± 0.075, p = 0.048).
conclusionThe detection of higher augmentation index and reflection magnitude in scarred patients might support the onset of subclinical atherosclerosis in these children. Higher serum sclerostin levels in scarred patients might be due to increased inflammation or arterial stiffness. Urinary galectin-3/cr could be used as tubular damage markers.
Indexed as
Identifiers
41249556What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.